15 Jan Mahzi Therapeutics
Posted at 20:45h
in
Yael Weiss, M.D., Ph.D., CEO
April 28 | 11:30am | Salone dei Cavalieri, Section 1
San Francisco, CA
(Private)
Mahzi specializes in developing genetic therapies for neurogenetic disorders that present clinically with seizures, autism and intellectual disabilities. Our lead program an AAV9 gene therapy for Pitt Hopkins Syndrome is now in a P1/2 study, with additional AAV gene therapy and ASO programs close behind. Mahzi works closely with PAtient Advocacy Groups to advance gene specific disease modifying therapies from bench to bedside.
